The Impact of Polymorphisms Distribution of Clopidogrel Metabolism Related Gene CYP2C19 on Stent Restenosis after PCI of CHD Patients

Hongxu ZHU,Liping SONG,Xuefeng GENG,Yufeng CHANG,Geng LIU
DOI: https://doi.org/10.3969/j.issn.1009-0959.2017.12.026
2017-01-01
Abstract:To explore the impact of polymorphisms distribution of clopidogrel metabolism related gene CYP 2C19 on stent restenosis after percutaneous coronary intervention(PCI)of CHD patients.Methods: 356 patients diagnosed CHD by coronary an-giogarphy and successfully underwent PCI treatment from January 2015 to August 2016 in our hospital were enrolled in the study.The post-operative incidence of stent restenosis within 12 months was recorded.Ploymerase chain reaction(PCR)and DNA sequencing methods were used to detect the genotypes of CYP 2C19 polymorphisms.We divided the patients into two groups by the result of the genotypes of CYP2C19 polymorphisms,one group was normal metabolize genotypes of CYP 2C19 polymorphisms, another group was intermediate and slower metabolize genotypes of CYP2C19 polymorphisms,which had CYP2C19*2 or CYP2C19*3.Results:The basic clinical data(in-cluding gender,age,BMI,LDL,HBA1C,systolic pressure,creatinine clearance rate,history of smoking and EF)had no statistical signifi-cance between two groups(P>0.05).We found there was a lower incidence of stent restenosis in patients with normal metabolize types of CYP2C19 polymorphisms than in patients with intermediate metabolize type and poor metabolize types CYP 2C19(P<0.05).Conclu-sion:Patients with coronary artery disease who have CYP 2C19*2 or CYP2C19*3 intermediate and slower metabolic genotype have in-creased incidence of stent restenosis after PCI.
What problem does this paper attempt to address?